{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:53:03Z","timestamp":1794840783443,"version":"4.9.1"},"reference-count":150,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.eururo.2023.03.013","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T16:28:35Z","timestamp":1679675315000},"page":"49-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":532,"title":["European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update"],"prefix":"10.1016","volume":"84","author":[{"given":"Morgan","family":"Roupr\u00eat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dominguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"G\u00fcrses Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hugh Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan P.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos N.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.03.013_b0005","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2023.03.013_b0010","series-title":"EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS)","author":"Gontero","year":"2023"},{"key":"10.1016\/j.eururo.2023.03.013_b0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0020","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1007\/s00345-020-03576-3","article-title":"Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study","volume":"39","author":"Alm\u00e5s","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-010-0594-7","article-title":"Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma","volume":"29","author":"Shariat","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2023.03.013_b0040","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/1878-0261.12325","article-title":"Molecular subtype classification of urothelial carcinoma in Lynch syndrome","volume":"12","author":"Therkildsen","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MOU.0000000000000340","article-title":"Lynch syndrome in upper tract urothelial carcinoma: significance, screening, and surveillance","volume":"27","author":"Pradere","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0050","doi-asserted-by":"crossref","first-page":"E583","DOI":"10.1111\/j.1464-410X.2012.11298.x","article-title":"A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool","volume":"110","author":"Audenet","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/PAS.0000000000001141","article-title":"Universal Lynch syndrome screening should be performed in all upper tract urothelial carcinomas","volume":"42","author":"Ju","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2023.03.013_b0060","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/ajcp\/aqaa100","article-title":"Universal mismatch repair protein screening in upper tract urothelial carcinoma","volume":"154","author":"Gayhart","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.eururo.2023.03.013_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.urology.2022.02.006","article-title":"Immunohistochemical screening of upper tract urothelial carcinomas for Lynch syndrome diagnostics: a systematic review","volume":"165","author":"Rasmussen","year":"2022","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.03.013_b0070","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/j.1464-410X.2009.08838.x","article-title":"Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract","volume":"104","author":"Colin","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0075","first-page":"254","article-title":"Cigarette smoking and cancers of the renal pelvis and ureter","volume":"52","author":"McLaughlin","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2023.03.013_b0080","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","article-title":"Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature","volume":"65","author":"Crivelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/em.21756","article-title":"Aristolochic acid nephropathy: harbinger of a global iatrogenic disease","volume":"54","author":"Grollman","year":"2013","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.eururo.2023.03.013_b0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200326010-00004","article-title":"Aristolochic acid and \u2018Chinese herbs nephropathy\u2019: a review of the evidence to date","volume":"26","author":"Cosyns","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.eururo.2023.03.013_b0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1055-9965.EPI-20-1090","article-title":"Additive effects of arsenic and aristolochic acid in chemical carcinogenesis of upper urinary tract urothelium","volume":"30","author":"Chen","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2023.03.013_b0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canep.2017.03.002","article-title":"Alcohol consumption and risk of upper-tract urothelial cancer","volume":"48","author":"Zaitsu","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.eururo.2023.03.013_b0105","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.juro.2017.06.020","article-title":"Stenting prior to cystectomy is an independent risk factor for upper urinary tract recurrence","volume":"198","author":"Kiss","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0110","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/JU.0000000000001548","article-title":"Does ureteral stenting increase the risk of metachronous upper tract urothelial carcinoma in patients with bladder tumors? A systematic review and meta-analysis","volume":"205","author":"Sountoulides","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0115","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ctrv.2010.12.005","article-title":"Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature","volume":"37","author":"Ouzzane","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2023.03.013_b0120","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","article-title":"Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis","volume":"203","author":"Mori","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/modpathol.3800559","article-title":"High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants","volume":"19","author":"Perez-Montiel","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2023.03.013_b0130","doi-asserted-by":"crossref","first-page":"458.e9","DOI":"10.1016\/j.urolonc.2017.02.010","article-title":"Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma","volume":"35","author":"Kim","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0135","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0140","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.ejso.2020.06.024","article-title":"Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: systematic review and meta-analysis","volume":"46","author":"Subiela","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0145","series-title":"TNM classification of malignant tumours","author":"Brierley","year":"2016"},{"key":"10.1016\/j.eururo.2023.03.013_b0150","unstructured":"WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. WHO classification of tumours, volume 8. ed. 5. Lyon, France: IARC; 2022."},{"key":"10.1016\/j.eururo.2023.03.013_b0155","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2023.03.013_b0160","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/cncr.24339","article-title":"Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality","volume":"115","author":"Inman","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0165","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrurol.2012.32","article-title":"CT urography for hematuria","volume":"9","author":"Cowan","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MOU.0000000000000899","article-title":"Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry","volume":"31","author":"Baard","year":"2021","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0175","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1464-410X.2007.06766.x","article-title":"Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour","volume":"99","author":"Cowan","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0180","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00345-019-02875-8","article-title":"Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis","volume":"38","author":"Janisch","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0185","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.juro.2009.12.031","article-title":"Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy","volume":"183","author":"Takahashi","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0190","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.acra.2012.05.004","article-title":"Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic","volume":"19","author":"Razavi","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1016\/j.eururo.2023.03.013_b0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euo.2019.09.004","article-title":"Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma","volume":"3","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","article-title":"Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma","volume":"31","author":"Cosentino","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0205","series-title":"The Paris system for reporting urinary cytology","year":"2022"},{"key":"10.1016\/j.eururo.2023.03.013_b0210","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","article-title":"Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma","volume":"108","author":"Messer","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/21681805.2017.1295102","article-title":"Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters","volume":"51","author":"Malm","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0220","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.urolonc.2011.07.011","article-title":"Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma","volume":"31","author":"Messer","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0225","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.crad.2009.11.003","article-title":"MR urography versus retrograde pyelography\/ureteroscopy for the exclusion of upper urinary tract malignancy","volume":"65","author":"Lee","year":"2010","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2023.03.013_b0230","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.urolonc.2012.05.010","article-title":"Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma","volume":"31","author":"Rojas","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0235","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.juro.2010.05.027","article-title":"Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract","volume":"184","author":"Ishikawa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0240","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/end.2011.0426","article-title":"High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection","volume":"26","author":"Clements","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.03.013_b0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.juro.2010.03.030","article-title":"Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma","volume":"184","author":"Brien","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0250","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000001834","article-title":"The impact of upper tract urothelial carcinoma diagnostic modality on intravesical recurrence after radical nephroureterectomy: a single institution series and updated meta-analysis","volume":"206","author":"Sharma","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0255","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.18632\/oncotarget.10708","article-title":"Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2023.03.013_b0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/JU.0000000000000788","article-title":"Differential effect of sex on outcomes after radical surgery for upper tract and bladder urothelial carcinoma: a systematic review and meta-analysis","volume":"204","author":"Mori","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0265","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Coll\u00e0 Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0270","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1111\/j.1464-410X.2011.10188.x","article-title":"Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study","volume":"108","author":"Matsumoto","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0275","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5114\/aoms.2019.89893","article-title":"Survival differences of patients with ureteral versus pelvicalyceal tumours: a systematic review and meta-analysis","volume":"17","author":"Kaczmarek","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.eururo.2023.03.013_b0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clgc.2019.10.023","article-title":"Urothelial carcinoma of the renal pelvis and ureter: does location make a difference?","volume":"18","author":"Lwin","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0285","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.clgc.2020.09.002","article-title":"The performance of tumor size as risk stratification parameter in upper tract urothelial carcinoma (UTUC)","volume":"19","author":"Foerster","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0290","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/ijms22020531","article-title":"Lynch syndrome: its impact on urothelial carcinoma","volume":"22","author":"Lindner","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2023.03.013_b0295","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.eururo.2012.06.029","article-title":"Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy","volume":"63","author":"Rink","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0300","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.12400","article-title":"Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy","volume":"114","author":"Xylinas","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0305","first-page":"9852","article-title":"Lymph node density for stratification of survival outcomes with node positive upper tract urothelial carcinoma","volume":"26","author":"Raza","year":"2019","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0310","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ejso.2018.12.004","article-title":"Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma","volume":"45","author":"Nazzani","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0315","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2009.08821.x","article-title":"A delay in radical nephroureterectomy can lead to upstaging","volume":"105","author":"Waldert","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0320","doi-asserted-by":"crossref","first-page":"10.e15","DOI":"10.1016\/j.urolonc.2017.09.013","article-title":"Impact of surgical waiting time on survival in patients with upper tract urothelial carcinoma: a National Cancer Database study","volume":"36","author":"Xia","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0325","doi-asserted-by":"crossref","first-page":"7386140","DOI":"10.1155\/2019\/7386140","article-title":"Prognostic value of lymphovascular invasion in upper urinary tract urothelial carcinoma after radical nephroureterectomy: a systematic review and meta-analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.eururo.2023.03.013_b0330","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bju.12369","article-title":"Predictors of survival in patients with disease recurrence after radical nephroureterectomy","volume":"113","author":"Kluth","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0335","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.urolonc.2014.04.008","article-title":"Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy","volume":"32","author":"Aziz","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0340","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1245\/s10434-012-2453-9","article-title":"Influence of positive surgical margin status after radical nephroureterectomy on upper urinary tract urothelial carcinoma survival","volume":"19","author":"Colin","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0345","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.urolonc.2009.12.003","article-title":"Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract","volume":"30","author":"Scarpini","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bju.12631","article-title":"Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and\/or locally advanced upper tract urothelial carcinoma without metastasis","volume":"114","author":"Seisen","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0355","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1002\/cam4.2988","article-title":"Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma","volume":"9","author":"Yoshida","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2023.03.013_b0360","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.juro.2016.09.078","article-title":"Postoperative nomogram for relapse-free survival in patients with high grade upper tract urothelial carcinoma","volume":"197","author":"Krabbe","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0365","doi-asserted-by":"crossref","DOI":"10.1177\/1559325819882872","article-title":"A model for the prediction of survival in patients with upper tract urothelial carcinoma after surgery","volume":"17","author":"Zhang","year":"2019","journal-title":"Dose Response"},{"key":"10.1016\/j.eururo.2023.03.013_b0370","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0375","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12253-019-00748-4","article-title":"Development and validation of a model for predicting intravesical recurrence in organ-confined upper urinary tract urothelial carcinoma patients after radical nephroureterectomy: a retrospective study in one center with long-term follow-up","volume":"26","author":"Zhang","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.eururo.2023.03.013_b0380","doi-asserted-by":"crossref","first-page":"19059","DOI":"10.1038\/s41598-021-98696-0","article-title":"Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy","volume":"11","author":"Sheu","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2023.03.013_b0385","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bju.14053","article-title":"Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis","volume":"121","author":"Guo","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0390","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non\u2013muscle invasive bladder cancer guidelines panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0395","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00345-015-1753-7","article-title":"Early repeated ureteroscopy within 6\u20138 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings","volume":"34","author":"Villa","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0400","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.urology.2016.05.033","article-title":"Survival comparison between endoscopic and surgical management for patients with upper tract urothelial cancer: a matched propensity score analysis using Surveillance, Epidemiology and End Results-Medicare data","volume":"95","author":"Vemana","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.03.013_b0405","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2006.07.019","article-title":"Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection","volume":"51","author":"Roupret","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0410","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.juro.2009.12.018","article-title":"Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter","volume":"183","author":"Jeldres","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0415","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1464-410X.2012.10960.x","article-title":"Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study","volume":"110","author":"Colin","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0420","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0425","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0430","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00345-008-0349-x","article-title":"Oncological risk of laparoscopic surgery in urothelial carcinomas","volume":"27","author":"Roupret","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euf.2017.10.003","article-title":"Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an European Association of Urology Guidelines systematic review","volume":"5","author":"Peyronnet","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.03.013_b0440","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eururo.2010.08.005","article-title":"Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?","volume":"58","author":"Favaretto","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0445","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1464-410X.2010.09826.x","article-title":"Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort","volume":"108","author":"Walton","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0450","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.eururo.2012.02.019","article-title":"Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies","volume":"61","author":"Ni","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0455","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1442-2042.2012.03110.x","article-title":"Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades","volume":"19","author":"Adibi","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0460","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1245\/s10434-018-6557-8","article-title":"Robotic-assisted surgery for upper tract urothelial carcinoma: a comparative survival analysis","volume":"25","author":"Clements","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0465","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.juro.2015.07.081","article-title":"Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma","volume":"194","author":"Aboumohamed","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0470","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2013.09.003","article-title":"Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0475","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1442-2042.2010.02610.x","article-title":"Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival","volume":"17","author":"Kondo","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0480","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.euf.2017.09.015","article-title":"Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology guidelines panel on non\u2013muscle-invasive bladder cancer","volume":"5","author":"Dominguez-Escrig","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.03.013_b0485","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/cncr.30516","article-title":"Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract","volume":"123","author":"Zareba","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0490","doi-asserted-by":"crossref","first-page":"33.e21","DOI":"10.1016\/j.urolonc.2016.07.022","article-title":"External validation of the pathological nodal staging score in upper tract urothelial carcinoma: a population-based study","volume":"35","author":"Xylinas","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0495","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0500","doi-asserted-by":"crossref","first-page":"10.e1","DOI":"10.1016\/j.urolonc.2021.05.014","article-title":"A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02","volume":"40","author":"Necchi","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0505","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.eururo.2012.04.052","article-title":"Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma","volume":"65","author":"Xylinas","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0510","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"O\u2019Brien","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0515","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial","volume":"31","author":"Ito","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0520","first-page":"CD013160","article-title":"Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma","volume":"2019","author":"Hwang","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2023.03.013_b0525","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000350508","article-title":"Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis","volume":"91","author":"Fang","year":"2013","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2023.03.013_b0530","doi-asserted-by":"crossref","first-page":"737.e11","DOI":"10.1016\/j.urolonc.2020.05.002","article-title":"Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy","volume":"38","author":"Freifeld","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0535","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1016\/j.clgc.2019.07.019","article-title":"Single versus maintenance intravesical chemotherapy for the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a randomized clinical trial","volume":"17","author":"Harraz","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0540","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2023.03.013_b0545","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0550","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.03.013_b0555","series-title":"European Commission approval for Opdivo (nivolumab) as adjuvant treatment for patients with radically resected, high-risk muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression \u22651%","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.eururo.2023.03.013_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103570","article-title":"Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes","volume":"169","author":"Laukhtina","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2023.03.013_b0565","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","article-title":"The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: a systematic review","volume":"37","author":"Iwata","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0570","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.03.013_b0575","doi-asserted-by":"crossref","first-page":"409.e9","DOI":"10.1016\/j.urolonc.2022.04.015","article-title":"Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: analysis of NCDB registry","volume":"40","author":"Piontkowski","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0580","doi-asserted-by":"crossref","first-page":"105.e19","DOI":"10.1016\/j.urolonc.2021.07.029","article-title":"Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study","volume":"40","author":"Shigeta","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0585","series-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer","author":"Witjes","year":"2023"},{"key":"10.1016\/j.eururo.2023.03.013_b0590","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.juro.2017.11.068","article-title":"Impact of primary tumor location on survival from the European Organization for the Research and Treatment of Cancer advanced urothelial cancer studies","volume":"199","author":"Moschini","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0595","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.21037\/tau-21-47","article-title":"Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature","volume":"10","author":"Gust","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0600","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0605","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2023.03.013_b0610","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0615","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0620","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/j.clgc.2021.12.017","article-title":"Evidence or prejudice? Critical re-analysis of randomized controlled trials comparing overall survival after cisplatin versus carboplatin-based regimens in advanced urothelial carcinoma","volume":"20","author":"Richters","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"18 Suppl","key":"10.1016\/j.eururo.2023.03.013_b0625","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA1","article-title":"Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis","volume":"38","author":"Powles","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0630","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0635","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2023.03.013_b0640","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.03.013_b0645","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0650","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0655","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0660","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0665","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0670","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.03.013_b0675","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.03.013_b0680","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0685","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/BLC-190252","article-title":"Docetaxel with or without ramucirumab after platinum-based chemotherapy and checkpoint inhibitors in advanced urothelial carcinoma: a pre-specified subgroup analysis from the phase 3 RANGE trial","volume":"6","author":"Drakaki","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0690","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","article-title":"Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database","volume":"3","author":"Moschini","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0695","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1016\/j.clgc.2019.03.003","article-title":"Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma","volume":"17","author":"Nazzani","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2023.03.013_b0700","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.eururo.2016.11.012","article-title":"Efficacy of systemic chemotherapy plus radical nephroureterectomy for metastatic upper tract urothelial carcinoma","volume":"71","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0705","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11255-011-9915-z","article-title":"Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status","volume":"43","author":"Simsir","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2023.03.013_b0710","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000052355","article-title":"Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor","volume":"37","author":"\u00d6ge","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0715","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-5347(05)00057-1","article-title":"Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome","volume":"175","author":"Holm\u00e4ng","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0720","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.juro.2017.06.073","article-title":"The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma","volume":"198","author":"Shigeta","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0725","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.euo.2022.04.003","article-title":"Oncologic surveillance after radical nephroureterectomy for high-risk upper tract urothelial carcinoma","volume":"5","author":"Martini","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.03.013_b0730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/21681805.2013.814706","article-title":"Long-term follow-up of patients with tumours of the renal pelvis and ureter: how often is a bladder tumour diagnosed after five tumour-free years?","volume":"48","author":"Holm\u00e4ng","year":"2014","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0735","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00345-016-1859-6","article-title":"Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma","volume":"35","author":"Mandalapu","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.03.013_b0740","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s11255-020-02439-5","article-title":"Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management","volume":"52","author":"Mohapatra","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2023.03.013_b0745","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DCR.0000000000002062","article-title":"Evaluation of urinalysis-based screening for urothelial carcinoma in patients with Lynch syndrome","volume":"65","author":"Chouhan","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.eururo.2023.03.013_b0750","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10689-008-9193-9","article-title":"Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer","volume":"7","author":"Myrh\u00f8j","year":"2008","journal-title":"Fam Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823026520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823026520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:14:12Z","timestamp":1759583652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823026520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0302283823026520"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}